Lineage Cell Therapeutics Inc (LCTX) Stock Analysis

Lineage Cell Therapeutics Inc (LCTX) is a publicly traded company in the HEALTHCARE sector. It trades at $1.21, carries a market capitalization of $331.57M. This page summarizes the public market data, fundamentals, and frequently asked questions for LCTX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

Market Sentiment

Lineage Cell Therapeutics Inc currently has a Bullish sentiment score of 0.23.

About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. is a forward-looking clinical-stage biotechnology firm based in Carlsbad, California, specializing in the development and commercialization of innovative cell-based therapies for degenerative diseases. With a strong emphasis on regenerative medicine, the company harnesses proprietary technologies to address significant unmet medical needs globally. Lineage boasts a robust and diverse pipeline supported by strategic collaborations, positioning it for substantial...

GNG Research Analysis

GNG Research scores Lineage Cell Therapeutics Inc (LCTX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for LCTX.

Frequently Asked Questions

Does LCTX pay dividends?

Lineage Cell Therapeutics Inc (LCTX) does not currently pay a regular dividend.

What is LCTX's market cap?

Lineage Cell Therapeutics Inc (LCTX) has a market capitalization of $331.57M with a current stock price of $1.21.